Nascent Biotech
Focus: Nascent Biotech is a San Diego-based antibody research company focused on oncology, currently in early-stage clinical development with a single Phase 1 program targeting malignant primary brain tumors.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Open Jobs
3-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Nascent Biotech?
AI assessmentNascent Biotech represents an early-stage, high-risk oncology platform suitable only for risk-tolerant professionals seeking equity upside and foundational impact in antibody science, with limited near-term revenue or career stability signals.
Why Work Here
- Early-stage oncology platform focused on antibody therapeutics, offering ground-floor opportunity to shape a core scientific program.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Pritumumab
Malignant Primary Brain TumorsClinical Trials (1)
NCT04396717Safety Study of Pritumumab in Brain Cancer
Phase 1Help build intelligence for Nascent Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.